MedPath

SYMBICORT® in the Treatment of COPD

Completed
Conditions
COPD
Registration Number
NCT00564499
Lead Sponsor
AstraZeneca
Brief Summary

A Scientific Research Program to evaluate the efficacy of SYMBICORT® 320/9μg in the treatment of COPD in real life environment by General Practitioners

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
Not specified
Inclusion Criteria
  • patients (m/f) with COPD (GOLD stadium III and IV)
Read More
Exclusion Criteria
  • patients who recently quit smoking (<3months)
Read More

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath